Show Summary Details
Page of

Heart Failure 

Heart Failure
Chapter:
Heart Failure
Author(s):

John McMurray

, Mark Petrie

, Karl Swedberg

, Michel Komajda

, Stefan Anker

, and Roy Gardner

DOI:
10.1093/med/9780199566990.003.023
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 22 August 2019

Although morbidity and mortality are improving, heart failure continues to present major challenges to healthcare systems. This affliction of mainly the elderly may be falling in incidence but is probably growing in prevalence, in part due to greater longevity resulting from evidence-based drug and device therapy for patients with a low ejection fraction (EF). New guidelines emphasize the combination of an angiotensin-converting enzyme inhibitor and beta-blocker as the cornerstone of therapy, with the addition of either an angiotensin receptor blocker or aldosterone antagonist as the third disease-modifying agent in patients who remain symptomatic. An implanted cardioverter defibrillator should also be added in patients with a persistently low EF and life expectancy of reasonable quality of ≥12 months. In patients in sinus rhythm, New York Heart Association class III–IV, and a QRS duration ≥120ms, cardiac resynchronization therapy has substantial additional morbidity and mortality benefits. This evidence-based care should be delivered through an organized and seamless multidisciplinary framework with a focus on the patients’ and carers’ needs. Apart from transplantation, the place of any other surgical intervention remains uncertain. Unfortunately the success of treatment in low EF heart failure has not been replicated in patients with heart failure and a preserved EF, and treatment of these patients remains empirical. The same is largely true for the treatment of patients with acute heart failure, with no treatment yet shown to be superior to empirical therapy with diuretic, oxygen, and nitrates. In particular the role of inotropes remains uncertain....

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.